Infections in Systemic Autoimmune Diseases: Risk Factors and Management

ISBN-13: 9780444642172 / Angielski

Fabiola Atzeni; Massimo Galli; Juan J. Gomez Reino

Recenzje

"This is a short yet comprehensive book describing infections in systemic autoimmune diseases. This series, with over 30 contributors and 15 predecessor volumes to this 16th volume, collectively presents a comprehensive resource for
rheumatologists, clinical immunologists, infectious disease specialists, and internists who are searching for updates on the subject." --Doody

Spis treści

1. The spectrum of infectious disease 2. Comorbidities in patients with rheumatic disease 3. Drugs used in rheumatic disease 4. Risk/benefit management in the infectious phase 5. Vaccine recommendations in patients with systemic rheumatic diseases 6. Education for patients/family and doctors

O autorze

Fabiola Atzeni, MD, PhD is currently Full Professor and Head of the Rheumatology Unit, University of Messina, Messina, Italy. Her clinical and research interest lies in immunotherapies in autoimmune diseases with particular focus on the investigation and management of differential response to biological therapies in rheumatoid arthritis (RA) and Spondyloarthritis (SpA), and cardiovascular aspects of the different rheumatic diseases with particular emphasis on arteriosclerosis. Dr. Atzeni has co-authored over 400 publications in peer-reviewed journals and several book chapters, is a regular reviewer for several international journals. She is involved in several international and national meetings focused on cardiovascular and infection aspects. Massimo is Doctor of medicine at the University of Milan. And director of the department of
infectious diseases Professor Juan Jose Gomez Reino MD is head of the rheumatology department at the University
of Santiago. Juan obtained his MD and PhD from the Autonomous University of Madrid, he
undertook his post doc training at the New York State University , Stony Brook USA. His clinical
research mainly focuses on the search for improved treatments for Rheumatoid Arthrosis and
Atherosclerosis which has resulted in many clinical treatment solutions. Dr Galloway is a clinical lecturer at King's College London and an honorary consultant in rheumatology at King's College Hospital. He runs the biologics assessment service for the rheumatology department. His research background has been in the study of biologic therapy safety. Within his role for KCL he works in the CRC accredited King's Clinical Trials Unit which has a large portfolio of investigator led trials. He also runs a phase 1 clinic in collaboration with the BRC facility and the Quintiles MHRA accredited Early Phase clinical trials unit at Guy's Hospital.